These fusions were both confirmed to be tumour-specific (Fig. 3b,f) and preserved the tyrosine kinase domain in the 3′ fusion partners RET and NTRK1, respectively (Fig. 3a,d,e,h). The gene discussed is NTRK1; the disease is neoplasm.